Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Decreases By 21.5%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 116,200 shares, a drop of 21.5% from the December 15th total of 148,000 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 208,200 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Ascendiant Capital Markets reiterated a “buy” rating and issued a $6.60 price objective on shares of Vivos Therapeutics in a report on Wednesday, November 20th. Alliance Global Partners reduced their price objective on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th.

Vivos Therapeutics Stock Performance

Vivos Therapeutics stock opened at $5.12 on Thursday. The company has a 50-day moving average price of $4.00 and a 200 day moving average price of $3.10. Vivos Therapeutics has a 12-month low of $1.91 and a 12-month high of $9.14.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.